1. bookVolume 26 (2019): Issue 4 (December 2019)
Journal Details
License
Format
Journal
First Published
01 May 2012
Publication timeframe
4 times per year
Languages
English
access type Open Access

The Relative Risk of Developing Type 2 Diabetes Mellitus in Young Adults with Schizophrenia Treated with Different Atypical Antipsychotic

Published Online: 17 Feb 2020
Page range: 445 - 453
Received: 29 Dec 2019
Accepted: 03 Jan 2020
Journal Details
License
Format
Journal
First Published
01 May 2012
Publication timeframe
4 times per year
Languages
English

Background and aim: While the link between antipsychotic treatment and metabolic adverse events, including type 2 diabetes mellitus (T2DM) are clear in adults with schizophrenia, in young this association is not so well studied although the use of secondgeneration antipsychotics (SGA) is more and more frequent.

Keywords

1. DeHert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10: 52–77, 2011.Search in Google Scholar

2. Ribe AR, Laursen TM, Sandbaek A et al. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol Med 44: 3097–3107, 2014.Search in Google Scholar

3. Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11- year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374: 620–627, 2009.Search in Google Scholar

4. Song SH, Hardisty CA. Early-onset Type 2 diabetes mellitus: an increasing phenomenon of elevated cardiovascular risk. Expert Rev Cardiovasc Ther 6: 315–322, 2008.Search in Google Scholar

5. Cohen D, Dekker JJ, Peen J, Gispen-de Wied CC. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur Neuropsychopharmacol 16: 187–194, 2006.Search in Google Scholar

6. Wilmot E, Idris I. Early onset type 2 diabetes: risk factors, clinical impact and management. Ther Adv Chronic Dis 5: 234–244, 2014.Search in Google Scholar

7. Narasimhan S, Weinstock RS. Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. Mayo Clin Proc 89: 806–816, 2014.Search in Google Scholar

8. Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy (letter). JAMA 162: 1651, 1956.Search in Google Scholar

9. Charatan FB, Bartlett NG. The effect of chlorpromazine (Largactil) on glucose tolerance. J Ment Sci 101: 351–353, 1955.Search in Google Scholar

10. Kirkpatrick B, Miller BJ, Garcia-Rizo C et al. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull 38: 280–284, 2012.Search in Google Scholar

11. Saddichha S, Manjunatha N, Ameen S et al. Diabetes and schizophrenia—effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 117: 342–347, 2008.Search in Google Scholar

12. Fernandez-Egea E, Miller B, Bernardo M et al. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 98: 302–306, 2008.Search in Google Scholar

13. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients (letter). Lancet 1: 495, 1989.Search in Google Scholar

14. Hansen T, Ingason A, Djurovic S et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 70: 59–63, 2011.Search in Google Scholar

15. Zhang X, Hui L, Liu Y et al. The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. J Clin Psychiatry 74: e287–e292, 2013.Search in Google Scholar

16. Irvin MR, Wiener HW, Perry RP et al. Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder. Schizophr Res 114: 50–56, 2009.Search in Google Scholar

17. Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 20(Suppl 4): S335–S339, 2005.Search in Google Scholar

18. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 123: 234–243, 2010.Search in Google Scholar

19. Liu Y, Li Z, Zhang M et al. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics 6(suppl 1): S17, 2013.Search in Google Scholar

20. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 47: S64–S66, 2004.Search in Google Scholar

21. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161: 1709–1711, 2004.Search in Google Scholar

22. Baker RA, Pikalov A, Tran QV et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 42: 11–31, 2009.Search in Google Scholar

23. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 37: 1–11, 2004.Search in Google Scholar

24. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(suppl 1): 1–93, 2005.Search in Google Scholar

25. De Hert M, Detraux J, van Winkel R et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8: 114–126, 2011.Search in Google Scholar

26. Smith M, Hopkins D, Peveler RC et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192: 406–411, 2008.Search in Google Scholar

27. Kessing LV, Thomsen AF, Mogensen UB et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 197: 266–271, 2010.Search in Google Scholar

28. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35: 1997–2004, 2010.Search in Google Scholar

29. Yood MU, DeLorenze G, Quesenberry CP Jr et al. The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18:791–799, 2009.Search in Google Scholar

30. Cohen D, De Hert M. Endogenic and iatrogenic diabetes mellitus in drug-naive schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm. Neuropsychopharmacology 36:2368–2369, 2011.Search in Google Scholar

31. Galling B, Roldán A, Nielsen RE et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and metaanalysis. JAMA Psychiatry 73: 247–259, 2016.Search in Google Scholar

32. Weston-Green K, Huang XF, Deng C. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs 27: 1069–1080, 2013.Search in Google Scholar

33. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during firsttime use in children and adolescents. JAMA 302(16): 1765-1773, 2009.Search in Google Scholar

34. Kryzhanovskaya LA, XuW, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of longterm (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 22(2): 157-165, 2012.Search in Google Scholar

35. Panagiotopoulos C, Ronsley R, Kuzeljevic B, Davidson J. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry 57(1): 34-44, 2012.Search in Google Scholar

36. Eapen V, John G. Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go? Australas Psychiatry 19(3): 232-235, 2011.Search in Google Scholar

37. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of secondgeneration antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 34(8): 651-668, 2011.Search in Google Scholar

38. DeHert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2): 114-126, 2012.Search in Google Scholar

39. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19(9): 629-635, 2009.Search in Google Scholar

40. Bobo WV, Cooper WO, Stein CM et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013 70(10): 1067-1075Search in Google Scholar

41. Galling B, Correll CU. Do antipsychotics increase diabetes risk in children and adolescents? Expert Opin Drug Saf 14(2): 219-241, 2015.Search in Google Scholar

42. Institutul Naţional de Statistică, Direcţia Judeţeană de Statistică Bihor.Anuarul statistic al judeţului Bihor 2017. Available at http://www.bihor.insse.ro (Accessed: 25 September, 2019), 2018.Search in Google Scholar

43. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M et al. Type 2 Diabetes Mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 73(3): 247–59, 2016.Search in Google Scholar

44. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 26(2): 219-230, 2013.Search in Google Scholar

45. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19(9): 629-635, 2009.Search in Google Scholar

46. D’Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care 34(suppl 2): S161-S165, 2011.Search in Google Scholar

47. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 369(9575): 1823-1831, 2007.Search in Google Scholar

48. Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaidenrolled youths. JAMA Pediatr 169(4): e150285, 2015.Search in Google Scholar

49. Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, et al. Endogenous and antipsychotic-related risks for Diabetes Mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry 174(7): 686–694, 2017.Search in Google Scholar

50. DeHert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and Type 2 Diabetes in Youth Exposed to Antipsychotics Original Investigation Research jamapsychiatry.com (Reprinted) JAMA Psychiatry 26(3): 144-158, 2016.Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo